Sato S, Kimura S, Nakamura T, Akuzawa Y, Kodama K, Furukawa K, Kurashige S
Department of Legal Medicine, School of Medicine, Gunma University, Japan.
Cancer Invest. 1998;16(1):18-25. doi: 10.3109/07357909809039749.
A significant inhibition of tumor growth was observed when sarcoma 180 (S180)-bearing ICR strain mice were treated by a combination therapy, with a low dose of cyclophosphamide (CY) and an inoculation of allogeneic lymphocytes collected from C57BL/6 mice. The growth-inhibitory effect was significantly increased by an inoculation of a relatively lower dose of allogeneic lymphocytes (1 x 10(5) cells) and CY. The effector cells induced in the mice treated with CY and allogeneic lymphocytes expressed the Lyt 1.2, Lyt 2.2, IL-2R antigens on their membrane surface and did not express the H2KbDb (donor H-2) antigen, and they showed a specific cytostatic activity against S180 cells. These results strongly suggested that a combination therapy with a low dose of CY with an inoculation of allogeneic lymphocytes augmented an induction of specific cytotoxic T lymphocytes in the tumor-bearing recipient mice.
当用低剂量环磷酰胺(CY)和接种从C57BL/6小鼠收集的同种异体淋巴细胞的联合疗法治疗携带肉瘤180(S180)的ICR品系小鼠时,观察到肿瘤生长受到显著抑制。通过接种相对较低剂量的同种异体淋巴细胞(1×10⁵个细胞)和CY,生长抑制作用显著增强。在用CY和同种异体淋巴细胞治疗的小鼠中诱导的效应细胞在其膜表面表达Lyt 1.2、Lyt 2.2、IL-2R抗原,不表达H2KbDb(供体H-2)抗原,并且它们对S180细胞表现出特异性细胞抑制活性。这些结果强烈表明,低剂量CY与同种异体淋巴细胞接种的联合疗法增强了荷瘤受体小鼠中特异性细胞毒性T淋巴细胞的诱导。